Commitment of parents and doctors of Irkutsk city to vaccine prophylaxis of whooping cough

2021 ◽  
pp. 48-51
Author(s):  
A.G. Petrova ◽  
T.A. Bayanova ◽  
A.S. Vanyarkina ◽  
E.A. Novikova ◽  
E.V. Moskaleva ◽  
...  
Keyword(s):  
Whooping Cough ◽  
Vaccine Prophylaxis

scholarly journals Modeling of the Potential Effect of Revaccination against Whooping Cough in Children Aged 6–7 and 14 years within the Framework of the National of preventive vaccinations

2021 ◽  
Vol 20 (5) ◽  
pp. 4-20
Author(s):  
N. I. Briko ◽  
A. Ya. Mindlina ◽  
I. V. Mikheeva ◽  
L. D. Popovich ◽  
A. V. Lomonosova
Keyword(s):  
Mathematical Model ◽  
Average Cost ◽  
Whooping Cough ◽  
Economic Effect ◽  
Living Will ◽  
Potential Effect ◽  
Economic Feasibility ◽  
Economic Damage ◽  
Public Benefits ◽  
Vaccine Prophylaxis

Relevance. Currently, the national calendar of preventive vaccinations does not provide for revaccination against whooping cough in children over the age of 18 months. At the same time, the epidemiological and economic feasibility of revaccination against whooping cough in children aged 6–7 years, as well as adolescents, has been demonstrated in world practice. Aim. Based on a mathematical model, develop a forecast of pertussis morbidity dynamics and assess the potential socio-economic damage under the current and expanded vaccine prophylaxis algorithms.Methods. Mathematical modeling of the potential effect of revaccination against whooping cough in children aged 6–7 years (scenario 1) and at 6–7 years and 14 years (scenario 2) was carried out within the framework of the national calendar of preventive vaccinations. A simulation dynamic mathematical model is constructed that allows predicting the development of the epidemiological process of whooping cough on the basis of the dynamics of the main indicators of its prevalence in the population that developed in previous years. The model took into account dynamic changes in the preventive effectiveness of vaccinations and the potential level of underestimation of morbidity. The obtained arrays of indicators served as the basis for extrapolating trends in morbidity and mortality until 2034.The calculation of epidemiological benefits was carried out in the metrics of prevented loss of years of life under the two scenarios under consideration in comparison with the current vaccination algorithm. The calculation of the economic effect was carried out on the basis of the obtained indicators of epidemiological benefits in the metrics of the monetary equivalent of the average cost of a year of life, taking into account the projected inflation coefficients until 2034.Results. The projected decrease in the number of years of life lived in a state of illness, in comparison with the current situation, will total 44.5 thousand years for the period 2019–2034 under scenario 1 and 66.7 thousand years under scenario 2. The socio-economic damage from prevented cases of the disease, expressed in the monetary equivalent of the average cost of living, will decrease by 28.6% (scenario 1) or 42.0% (scenario 2).Conclusions. A comparison of the received public benefits with the costs of vaccination shows that the expansion of the NCPP with additional revaccinations against whooping cough (at 6–7 years or at 6–7 and at 14 years) is advisable both in epidemiological and economic aspects.

WHOOPING-COUGH NOTIFICATIONS

The Lancet ◽  
1980 ◽  
Vol 315 (8167) ◽  
pp. 718
Author(s):  
E Miller
Keyword(s):  
Whooping Cough

CLINICAL AND LABORATORY PECULIARITIES OF WHOOPING COUGH IN CHILDREN OF DIFFERENT AGE GROUPS

2020 ◽  
Vol 99 (6) ◽  
pp. 98-104
Author(s):  
I.V. Babachenko ◽  
◽  
Y.V. Nesterova ◽  
N.V. Skripchenko ◽  
◽  
...  
Keyword(s):  
Whooping Cough ◽  
Severe Disease ◽  
Respiratory Rhythm ◽  
Age Groups ◽  
Low Frequency ◽  
Pertussis Infection ◽  
Group 2 ◽  
Sick Children ◽  
Hematological Changes ◽  
Group 1

Objective of the research: to present the clinical and laboratory peculiarities of modern whooping cough in hospitalized children of different ages. Materials and methods: сlinical and laboratory characteristics of whooping cough were analyzed in 88 hospitalized sick children aged 1 month to 18 years in groups of children: group 1 – children under 1 year old; group 2 – children 1–6 years old; group 3 – children 7–17 years old. DNA of causative agents of pertussis infection was isolated by PCR in nasopharyngeal swabs using a commercial kit AmpliSens®Bordetella multi-FL (Moscow). Results: children of group 1 in 90% (n=43) of cases were not vaccinated against whooping cough, severe forms were recorded in 17% (n=8) of children of the 1st year of life, and in 15% (n=7) – due to respiratory rhythm disturbances. The diagnosis was confirmed by PCR in 94% (n=45) of children, leukocytosis with lymphocytosis was detected in 81,5% (n=101). Along with hematological changes typical for whooping cough, 79% (n=38) of patients in the first year of life had thrombocytosis (>400×109/l), which was most pronounced in severe disease course 511,5 [425; 568,5]×109/l vs 421 [347; 505,5]×109/l; p<0,05, which has no tendency to decrease throughout the entire observation period and correlates with the level of leukocytes (rs=0,69; p<0,001). Patients over 7 years old in 88% (n=21) of cases were vaccinated against whooping cough, but 79% (n=27) hemograms had no characteristic changes, which, along with a low frequency of confirmation of the diagnosis by PCR 22% (n=4), made it difficult to diagnose whooping cough. Conclusion: children over 7 years of age may not have characteristic hematological changes and PCR diagnostics are insufficiently effective, which contributes to the spread of whooping cough in family foci.

April 20 to 26, 2020 – World Immunization Week

2020 ◽  
pp. 76-79
Author(s):  
Oksana Rybachok
Keyword(s):  
Western Europe ◽  
Whooping Cough ◽  
Developed Countries ◽  
World Health ◽  
Modern World ◽  
Pneumococcal Infections ◽  
Preventive Vaccination ◽  
The Russian Federation ◽  
Health Organization ◽  
The Third World

Infectious diseases in the modern world continue to claim millions of human lives despite the achievements of medicine. While in developed countries the main cause of death is cancer and diseases of the cardiovascular system, it is the infectious processes that occupy leading positions in the structure of mortality in the third world countries. About 1.7 million children die from infections that could have been avoided by vaccination according to the World Health Organization. In contrast to the countries of Western Europe, where preventive vaccinations for the population are carried out for a fee, preventive vaccination in the Russian Federation is funded by the state. Immunoprophylaxis includes not only prevention of 12 major infections included in the calendar of preventive vaccinations (diphtheria, polio, tetanus, whooping cough, tuberculosis, measles, rubella, mumps, hepatitis B, pneumococcal infections and haemophilus influenzae, influenza), but also vaccination against 17 additional infections in case of epidemiological indications.

Visnagin: A New Perspective of Medicinal Importance, Physiological Functions, Phytochemistry, Pharmacology and Analytical Aspects of Active Phytoconstituents of Ammi visnaga

2019 ◽  
Vol 9 (3) ◽  
pp. 197-206
Author(s):  
Kanika Patel ◽  
Mahfoozur Rahman ◽  
Vikas Kumar ◽  
Amita Verma ◽  
Dinesh Kumar Patel
Keyword(s):  
Angina Pectoris ◽  
Renal Colic ◽  
Whooping Cough ◽  
Analytical Techniques ◽  
Epileptic Seizures ◽  
Coronary Insufficiency ◽  
Ammi Visnaga ◽  
Low Blood Pressure ◽  
Annual Herb ◽  
New Perspective

Background: Ammi visnaga commonly known as ‘honey plant, tooth pick fruit, bisnaga and khella’ is an important plant of Apiaceae family. It is an annual herb found in Europe, Asia, North Africa, Latin America and in India. Carrot, parsnip, celery, coriander, anise, caraway, cumin, parsley and dill are some other plants of the same family i.e., ‘Apiaceae’. Fruits of Ammi visnaga (A. visnaga) are medicinally used as a strong photosensitizer, diaphoretic, carminative and antispasmodic agents. Objective: A. visnaga has been used for the treatment of bronchial asthma, coronary insufficiency, angina pectoris, psoriasis, renal colic and ureteric stones. Visnagin (C13H10O4) is a ‘furanochromone derivative’ which is the main active constituent’s of A. visnaga. Visnagin is used for the treatment of low blood-pressure, angina pectoris and kidney stone. It also has neuroprotective and antiinflammatory activity. Moreover, visnagin also treat whooping cough, ureter and bile duct, gall bladder and renal colic, tumors and epileptic seizures. Methods: This review summarizes data’s regarding the biological importance, pharmacological uses and medicinal importance of A. visnaga and their important active constituent’s “visnagin”. Moreover, the detailed pharmacological aspects of visnagin were presented in this review. Further various analytical techniques used for the extraction and isolation of visnagin were also discussed. Studies related to the pharmacological profile of the plants and their active phytoconstituents are one of the leading areas of research. Conclusion: This review will be beneficial to the scientific society to understand the importance of A. visnaga plant and their active constituents ‘visnagin’for the development of alternative tools to treat disorders in the future.

SARS-CoV-2 Biology Insights, Part IV.Antibody-Dependent Enhancement (ADE) and the tricky “Herd Immunity”: narrative review (Preprint)

2020 ◽  
Author(s):  
Laura Lafon-Hughes
Keyword(s):  
Viral Infection ◽  
Viral Entry ◽  
Neutralizing Antibodies ◽  
Vaccine Development ◽  
Whooping Cough ◽  
Common Knowledge ◽  
Herd Immunity ◽  
Life Quality ◽  
Host Cells ◽  
System P

BACKGROUND It is common knowledge that vaccination has improved our life quality and expectancy since it succeeded in achieving almost eradication of several diseases including chickenpox (varicella), diphtheria, hepatitis A and B, measles, meningococcal, mumps, pneumococcal, polio, rotavirus, rubella, tetanus and whooping cough (pertussis) Vaccination success is based on vaccine induction of neutralizing antibodies that help fight the infection (e.g. by a virus), preventing the disease. Conversely, Antibody-dependent enhancement (ADE) of a viral infection occurs when anti-viral antibodies facilitate viral entry into host cells and enhance viral infection in these cells. ADE has been previously studied in Dengue and HIV viruses and explains why a second infection with Dengue can be lethal. As already reviewed in Part I and Part II, SARS-Cov-2 shares with HIV not only 4 sequences in the Spike protein but also the capacity to attack the immune system. OBJECTIVE As HIV presents ADE, we wondered whether this was also the case regarding SARS-CoV-2. METHODS A literature review was done through Google. RESULTS SARS-CoV-2 presents ADE. As SARS, which does not have the 4 HIV-like inserts, has the same property, ADE would not be driven by the HIV-like spike sequences. CONCLUSIONS ADE can explain the failure of herd immunity-based strategies and will also probably hamper anti-SARS-CoV-2 vaccine development. As reviewed in Part I, there fortunately are promising therapeutic strategies for COVID-19, which should be further developed. In the meantime, complementary countermeasures to protect mainly the youth from this infection are presented to be discussed in Part V Viewpoint.

Sign in / Sign up

Export Citation Format

Share Document